However, this problem may be overcome by new active drugs such as cabazitaxel. BMs should be distinguished from other CNS metastases. The term BM should be limited to the focal seeding of the ...

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...

Cabazitaxel's recent FDA approval makes it a suitable option for patients with disease progression post-docetaxel. Recent improvements in overall survival with the use of abiraterone following ...

Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...

APCCC Diagnostics annual meeting featured a session on what we should know for PSMA radioligand therapy and a presentation by Dr. Andrei Gafita discussing prognostic, predictive and response ...